RecruitingNCT03995121

SV2 PET Imaging With [11C]APP311

Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311

Sponsor

Yale University

Enrollment

250 participants

Start Date

Dec 1, 2017

Study Type

OBSERVATIONAL

Conditions

Healthy Cannabis Use Disorder Schizophrenia and Other Psychotic Disorders

Summary

The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria2

Willing and able to give voluntary written informed consent
Male and Female subjects, age 18 to 65 years, inclusive

Exclusion Criteria2

MRI metal exclusions and claustrophobia.
Education completed is less than 12 years

Interventions

DRUG[11C]APP311

It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.